Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 15/20 | 0.41 |
| ▸ | XIAP | P98170 | 14/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487700 | 0.84 | GLS (0.39) | P2RX7NPC1RAB9A | |
| SCHEMBL25487707 | 0.84 | GLS (0.39) | P2RX7NPC1RAB9A | |
| SCHEMBL25487531 | 0.77 | NR3C1 (0.37) | P2RX7 | |
| SCHEMBL25487994 | 0.75 | P2RX7 (0.35) | P2RX7SMN1; SMN2 | |
| SCHEMBL25487525 | 0.73 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL25487830 | 0.72 | LIMK1 (0.35) | P2RX7LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL25487882 | 0.72 | P2RX7 (0.36) | P2RX7SMN1; SMN2 | |
| SCHEMBL25490145 | 0.71 | KDM4E (0.37) | P2RX7LMNAMAPTHTTNPC1 | |
| SCHEMBL25487709 | 0.70 | MEN1 (0.36) | P2RX7NPC1RAB9A | |
| SCHEMBL25487572 | 0.70 | ALDH1A1 (0.36) | LMNAMAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | WEE2, WEE1, CDK2 | BIRC2 1290/4885XIAP 793/4885P2RX7 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.